Rocket's Third-Quarter 2026 Net Loss Narrows to $49.2 Million

The Tip Desk · November 13, 2026 · 4 min read

Third-quarter 2026 R&D expenses fell to $31.2 million from $34.1 million a year earlier. Cash, cash equivalents and investments stood at $279.4 million as of September 30, 2026, including a $35 million Hercules draw, with operations expected to be funded into the third quarter of 2028.

Rocket Pharmaceuticals (RCKT), a commercial-stage biotechnology company developing genetic medicines for rare diseases with a focus on inherited cardiovascular disorders, reported a third-quarter 2026 net loss of $49.2 million, compared with $50.3 million a year earlier. Research and development expenses fell to $31.2 million from $34.1 million. The company said the FDA aligned on the path to complete the pivotal Phase 2 trial of RP-A501 in Danon disease, with dosing expected to finish by mid-2027 and topline results anticipated in mid-2028.

On September 15, the company announced alignment on continued enrollment and dosing and key elements of the global pivotal study, including the recalibrated dose, a 12-patient pivotal population and 12-month co-primary endpoints. The first three patients treated under the modified protocol count toward that 12-patient efficacy population. At the 12-month assessment, at least seven of the 12 patients must show both myocardial LAMP2 expression at Grade 1 or higher and a decrease of 10% or more from baseline in left ventricular mass index to meet the pivotal efficacy success criterion. The company said the co-primary endpoints are intended to support a potential accelerated approval pathway.

Chief Executive Officer Gaurav Shah said the priority is to complete dosing by mid-2027. On October 6, Rocket hosted an investor webinar highlighting updated longer-term Phase 1 findings and encouraging initial safety observations in those first three patients. The company reviewed independent genotype- and phenotype-based analyses estimating 10,000–11,000 people living with Danon disease in the U.S., including approximately 4,000 males, and said it has identified more than 900 Danon patients.

The cardiovascular pipeline advanced on other fronts. Dosing was initiated in the Phase 1 trial of RP-A701 for BAG3-associated dilated cardiomyopathy, a multicenter, dose-escalation study in adults. On October 20, the European Commission granted orphan designation to RP-A701 for BAG3-DCM. Rocket continues to advance RP-A601 for PKP2 arrhythmogenic cardiomyopathy through an ongoing Phase 1 study and FDA engagement on a potential pivotal study.

KRESLADI (marnetegragene autotemcel), the autologous hematopoietic stem cell gene therapy for severe leukocyte adhesion deficiency-I, achieved commercial readiness on October 1, 2026. Two Qualified Treatment Centers were activated and ready to begin commercial patient onboarding, and the company’s external manufacturing network is in place. The second-quarter release had said preparations were underway for commercial availability and patient onboarding beginning in the fourth quarter of 2026.

On October 6, Rocket announced a credit facility with Hercules Capital for up to $150 million to support the pivotal RP-A501 trial and the broader cardiovascular pipeline. It received $35 million at closing and may draw an additional $35 million at its option during specified periods. An additional $30 million may become available upon a specified Danon clinical milestone, and $50 million is subject to Hercules’ investment committee approval.

Cash, cash equivalents and investments were $279.4 million as of September 30, 2026, including the initial Hercules draw. Based on its current operating plan, Rocket expects that cash to fund operations into the third quarter of 2028. Additional borrowings could extend runway into 2029, subject to borrowing conditions, draw timing and amounts, and operating expenditures.

Net loss was $49.2 million, or $0.43 a share (basic and diluted), for the three months ended September 30, 2026, compared with $50.3 million, or $0.45 a share, a year earlier.

Research and development expenses were $31.2 million for the three months ended September 30, 2026, compared with $34.1 million a year earlier. The company said the $2.9 million decrease was primarily driven by reductions in stock-based and other compensation and benefits of $3.5 million due to decreased R&D headcount, manufacturing and development and direct material costs of $1.9 million, and depreciation of $1.2 million, partly offset by higher laboratory-related expenses of $1.4 million, professional fees of $1.4 million, and clinical trial expenses of $0.6 million.

General and administrative expenses were $19.8 million, compared with $18.4 million a year earlier. The company attributed the $1.4 million increase primarily to $3.4 million of post-marketing commitment expenses and $0.6 million of commercial-preparation expenses, partly offset by lower stock-based compensation and legal expenses.

Other income was $1.8 million. Income taxes were $0.1 million. Weighted-average shares outstanding were 113,647,401 basic and diluted for the three months ended September 30, 2026.

Shah said financial resources and the Hercules facility support the company’s priorities as it works toward its next clinical and commercial milestones.